Kajáry Kornélia, Lengyel Zsolt, Tőkés Anna-Mária, Kulka Janina, Dank Magdolna, Tőkés Tímea
Pozitron PET/CT Center, Hunyadi J. Str. 9, Budapest, H-1117, Hungary.
Semmelweis University 2nd Department of Pathology, Üllői str. 93., Budapest, H-1091, Hungary.
Pathol Oncol Res. 2020 Apr;26(2):997-1006. doi: 10.1007/s12253-019-00641-0. Epub 2019 Apr 3.
Our aim was to evaluate correlation between clinicopathological features (clinical T and clinical N stages; histological type; nuclear grade; hormone-receptor and HER2 status, proliferation activity and tumor subtypes) of breast cancer and kinetic parameters measured by staging dynamic FDG-PET/CT examinations. Following ethical approval and patients' informed consent we included 34 patients with 35 primary breast cancers in our prospective study. We performed dynamic PET imaging, and assessed plasma activity noninvasively. To delineate primary tumors we applied a frame-by-frame semi-automatic software-based correction of motion artefacts. FDG two-compartment kinetic modelling was applied to assess K1, k2, k3 rate coefficients and to calculate Ki (tracer flux constant) and MRFDG (FDG metabolic rate). We found that k3, Ki and MRFDG were significantly higher in higher grade (p = 0.0246, 0.0089 and 0.0076, respectively), progesterone-receptor negative (p = 0.0344, 0.0217 and 0.0132) and highly-proliferating (p = 0.0414, 0.0193 and 0.0271) tumors as well as in triple-negative and hormone-receptor negative/HER2-positive subtypes (p = 0.0310, 0.0280 and 0.0186). Ki and MRFDG were significantly higher in estrogen-receptor negative tumors (p = 0.0300 and 0.0247, respectively). Ki was significantly higher in node-positive than in node-negative disease (p = 0.0315). None of the assessed FDG-kinetic parameters showed significant correlation with stromal TIL. In conclusion, we confirmed a significant relationship between kinetic parameters measured by dynamic PET and the routinely assessed clinicopathological factors of breast cancer: high-grade, hormone-receptor negative tumors with high proliferation rate are characterized by higher cellular FDG-uptake and FDG-phosphorylation rate. Furthermore, we found that kinetic parameters based on the dynamic examinations are probably not influenced by stromal TIL infiltration.
我们的目的是评估乳腺癌的临床病理特征(临床T和临床N分期、组织学类型、核分级、激素受体和HER2状态、增殖活性及肿瘤亚型)与分期动态FDG-PET/CT检查所测量的动力学参数之间的相关性。在获得伦理批准及患者知情同意后,我们将34例患有35个原发性乳腺癌的患者纳入前瞻性研究。我们进行了动态PET成像,并对血浆活性进行了无创评估。为了勾勒原发性肿瘤,我们逐帧应用了基于软件的半自动运动伪影校正。应用FDG两室动力学模型来评估K1、k2、k3速率系数,并计算Ki(示踪剂通量常数)和MRFDG(FDG代谢率)。我们发现,在高级别(分别为p = 0.0246、0.0089和0.0076)、孕激素受体阴性(p = 0.0344、0.0217和0.0132)和高增殖性(p = 0.0414、0.0193和0.0271)肿瘤以及三阴性和激素受体阴性/HER2阳性亚型(p = 0.0310、0.0280和0.0186)中,k3、Ki和MRFDG显著更高。在雌激素受体阴性肿瘤中,Ki和MRFDG显著更高(分别为p = 0.0300和0.0247)。Ki在淋巴结阳性疾病中显著高于淋巴结阴性疾病(p = 0.0315)。所评估的FDG动力学参数均未显示与基质TIL有显著相关性。总之,我们证实了动态PET测量的动力学参数与乳腺癌常规评估的临床病理因素之间存在显著关系:高分级、激素受体阴性且增殖率高的肿瘤具有更高的细胞FDG摄取和FDG磷酸化率。此外,我们发现基于动态检查的动力学参数可能不受基质TIL浸润的影响。